bullish

Biocon Ltd

Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction

269 Views14 Sep 2022 19:38
SUMMARY
  • Biocon Ltd (BIOS IN) divested 5.4% stake in Syngene International Ltd (SYNG IN) and raised INR12.2B. The proceed will be used to finance Biocon’s acquisition of biologics business of Viatris.
  • Biocon is still working on the equity-debt split of Viatris deal, and a final decision on the same will be announced soon.
  • The strategic deal with Viatris will transform Biocon Biologics into a leading vertically integrated global biologics company, with one of the broadest and deepest commercialized biosimilars portfolio in the industry.
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Analytics & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction
    14 Sep 2022
x